Ireland - English - HPRA (Health Products Regulatory Authority)

merial animal health limited - inactivated porcine parovirus, k-22 strain, erysipelothrix rhusiopathiae (lysed bacterial cells), serotype 2 - suspension for injection - unknown - inactivated porcine parvovirus vaccine + inactivated erysipelothrix vaccine - porcine - immunological - inactivated vaccine

European Union - English - EMA (European Medicines Agency)

laboratorios hipra, s.a. - porcine parvovirus, strain nadl-2 and erysipelothrix rhusiopathiae, strain r32e11 (inactivated) - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of female pigs for the protection of progeny against transplacental infection caused by porcine parvovirus.for the active immunisation of male and female pigs to reduce clinical signs (skin lesions and fever) of swine erysipelas caused by erysipelothrix rhusiopathiae, serotype 1 and serotype 2.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - split influenza virus, inactivated, containing antigen: a/vietnam/1194/2004 (h5n1) like strain used (nibrg-14) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of vaccine prepared from a/vietnam/1194/2004 nibrg-14 (h5n1) (see section 5.1).prepandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals 3.75 µg should be used in accordance with official guidance.

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - equine rotavirus h2 strain - emulsion for injection - equine rotavirus - equine - food - immunological - inactivated vaccine

New Zealand - English - Ministry for Primary Industries

zoetis new zealand limited - escherichia coli k99 (pili); bovine rotavirus (inactivated); bovine coronavirus (inactivated) - escherichia coli k99 (pili) 0 vaccine; bovine rotavirus (inactivated) 0 vaccine; bovine coronavirus (inactivated) 0 vaccine - vaccine

New Zealand - English - Ministry for Primary Industries

phoenix pharm distributors ltd - bovine coronavirus, strain c-197, inactivated; escherichia coli k99 (pili); bovine rotavirus, strain tm-91, inactivated - bovine coronavirus, strain c-197, inactivated 0 vaccine; escherichia coli k99 (pili) 0 vaccine; bovine rotavirus, strain tm-91, inactivated 0 vaccine - vaccine

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - diphtheria toxoid; haemophilus influenza type b conjugate; tetanus toxoid; pertussis toxoid (pt); filamentous haemagglutinin (fha); inactivated poliomyelitis virus,type 3; inactivated poliomyelitis virus,type 2; inactivated poliomyelitis virus,type 1 -

Ireland - English - HPRA (Health Products Regulatory Authority)

animal health distributors limited - bovine respiratory syncytial virus, strain bio-24 inactivated; bovine parainfluenza 3 virus, strain bio-23, inactivated; mannheimia haemolytica, serotype a1 strain dsm 5283, inactivated - suspension for injection - . relative potency/dose - bovine parainfluenza virus + bovine respiratory syncytial virus + pasteurella

European Union - English - EMA (European Medicines Agency)

cz veterinaria s.a. - bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated] - immunologicals - sheep, cattle - sheepactive immunisation against bluetongue virus serotype 8 to prevent viraemia and to reduce clinical signs.onset of immunity: 20 days after second dose.duration of immunity: 1 year after second dose.cattleactive immunisation against bluetongue virus serotype 8 to prevent viraemia.onset of immunity: 31 days after second dose.duration of immunity: 1 year after second dose.

European Union - English - EMA (European Medicines Agency)

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - vaccines - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age. the use of this vaccine should be in accordance with official recommendations.